Baseline characteristics of the 155 patients with RUNX1-RUNX1+ AML
| Characteristic . | Data . |
|---|---|
| Median age, years (range) | 47 (18-76) |
| Male sex, n (%) | 86 (55) |
| AML history, n (%) | |
| De novo | 132 (90) |
| Secondary | 2 (2) |
| Therapy-related | 12 (8) |
| Missing data, n | 9 |
| Median WBC, ×109/L (range) | 8.8 (1.2-117.5) |
| Missing data, n | 9 |
| Median platelet count, ×109/L (range) | 29 (3-303) |
| Missing data, n | 4 |
| Median hemoglobin, g/dL (range) | 9.0 (3.8-15.1) |
| Missing data, n | 4 |
| Median PB blasts, % (range) | 41 (0-99) |
| Missing data, n | 18 |
| Median BM blasts, % (range) | 60 (6-100) |
| Missing data, n | 14 |
| Median LDH, U/L (range) | 476.5 (5-4420) |
| Missing data, n | 9 |
| KIT mutation, n (%) | 39 (28) |
| Missing data, n | 17 |
| FLT3-ITD/TKD mutation, n (%) | 14 (9) |
| Missing data, n | 1 |
| NRAS mutation, n (%) | 24 (17) |
| Missing data, n | 17 |
| ASXL2 mutation, n (%) | 18 (19) |
| Missing data, n | 58 |
| Characteristic . | Data . |
|---|---|
| Median age, years (range) | 47 (18-76) |
| Male sex, n (%) | 86 (55) |
| AML history, n (%) | |
| De novo | 132 (90) |
| Secondary | 2 (2) |
| Therapy-related | 12 (8) |
| Missing data, n | 9 |
| Median WBC, ×109/L (range) | 8.8 (1.2-117.5) |
| Missing data, n | 9 |
| Median platelet count, ×109/L (range) | 29 (3-303) |
| Missing data, n | 4 |
| Median hemoglobin, g/dL (range) | 9.0 (3.8-15.1) |
| Missing data, n | 4 |
| Median PB blasts, % (range) | 41 (0-99) |
| Missing data, n | 18 |
| Median BM blasts, % (range) | 60 (6-100) |
| Missing data, n | 14 |
| Median LDH, U/L (range) | 476.5 (5-4420) |
| Missing data, n | 9 |
| KIT mutation, n (%) | 39 (28) |
| Missing data, n | 17 |
| FLT3-ITD/TKD mutation, n (%) | 14 (9) |
| Missing data, n | 1 |
| NRAS mutation, n (%) | 24 (17) |
| Missing data, n | 17 |
| ASXL2 mutation, n (%) | 18 (19) |
| Missing data, n | 58 |
ITD, internal tandem duplication; TKD, tyrosine kinase domain.